scout
|Videos|November 4, 2022

The Rationale for PARP Inhibitor Treatment for HRD-Positive Ovarian Cancer

Dr Shannon Westin shares if and when she could justify withholding a PARP inhibitor from a patient with HRD-positive ovarian cancer.

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME